2024-11-02 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a multinational pharmaceutical company that develops and markets a wide range of biopharmaceutical products, including Humira, a blockbuster drug for autoimmune diseases.

**1. Performance vs. S&P 500:**

* **Cumulative Return:** ABBV has a cumulative return of 164.98% compared to 131.38% for the S&P 500 (VOO). This translates to a 33.6% difference.
* **Relative Outperformance:** ABBV's relative outperformance compared to the S&P 500 is currently at the 73.6th percentile based on historical data. 

**2. Recent Price Movement:**

* **Closing Price:** $203.87 (Last Market: $204.2)
* **Moving Averages:**
    * 5-day: $194.47
    * 20-day: $192.24
    * 60-day: $193.85

**3. Technical Indicators:**

* **RSI:** 64.11. This indicates the stock is in overbought territory, but not significantly so.
* **PPO:** 0.68.  A positive value suggests potential for continued upward momentum.
* **Delta_Previous_Relative_Divergence:** 9.65 (+). A positive value suggests a short-term upward trend. 
* **Expected Return:** 1.51%.  A 1.51% expected return over the long term (2 years or more) suggests potential for outperforming the S&P 500. 

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Expected EPS |
|------------|---------|---------------|
| 2024-10-30 | 3       | 2.92         |
| 2024-07-25 | 2.65    | 2.57         |
| 2024-04-26 | 2.31    | 2.26         |
| 2024-02-02 | 2.79    | 2.76         |
| 2023-10-27 | 2.95    | 2.86         |

**Analysis:** AbbVie has consistently exceeded earnings expectations in recent quarters. The most recent quarter (2024-10-30) showed an EPS of 3, surpassing the expected EPS of 2.92. This suggests strong performance and potential for continued growth.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter       | Revenue     | Profit Margin |
|------------|---------|---------------|
| 2024-06-30 | $14.46B   | 70.94%       |
| 2024-03-31 | $12.31B   | 66.74%       |
| 2023-12-31 | $14.30B   | 60.11%       |
| 2023-09-30 | $13.93B   | 53.44%       |
| 2023-06-30 | $13.87B   | 69.42%       |

**Analysis:** AbbVie has maintained strong revenue growth and profitability over the past year. The company consistently generates high profit margins, indicating efficient operations and a strong market position.

**2) Capital and Profitability:**

| Quarter       | Equity      | ROE          |
|------------|---------|---------------|
| 2024-06-30 | $6.78B   | 20.21%       |
| 2024-03-31 | $8.01B   | 17.10%       |
| 2023-12-31 | $10.36B  | 7.93%        |
| 2023-09-30 | $12.09B  | 14.70%       |
| 2023-06-30 | $12.87B  | 15.73%       |

**Analysis:** AbbVie's equity and return on equity (ROE) have fluctuated over the past year. The ROE has been consistently above average, reflecting the company's strong profitability and efficiency.

**6. News and Recent Issues:**

* **Earnings News:**  The latest earnings release for AbbVie (2024-10-30) was generally well-received by the market, with the stock price showing a positive reaction following the announcement. 
* **Market Outlook:** The current market sentiment towards ABBV is positive, driven by the company's strong financial performance and consistent earnings growth. 
* **Analyst Opinions:** Most analysts maintain a "buy" or "strong buy" rating on ABBV, citing the company's strong track record and growth potential. 

**7. Overall Analysis:**

* AbbVie is a financially strong company with a solid track record of growth and profitability.
* The company's recent earnings results have exceeded expectations, indicating positive momentum.
* Technical indicators suggest the stock may be slightly overbought, but still has potential for continued upward movement. 
* Analyst opinions are generally positive, supporting the idea of strong future performance. 

**Conclusion:** ABBV presents a potentially attractive investment opportunity for long-term investors seeking growth and solid returns. The company's strong financial performance, consistent earnings growth, and positive market sentiment suggest continued success in the future. However, it is important to consider the potential for short-term volatility due to the overbought status of the stock. 
